Table 4.
Log-rank analysis comparing overall survival in medication groups to no anti-inflammatory medication groups across all, cachectic, and non-cachectic cohorts.
| All patients (n=3180) | Cachectic patients (n=1083) | Non-cachectic patients (n=2097) | ||||
|---|---|---|---|---|---|---|
| Prior medication use | Median time (95% CI)(months) | P-value log-rank | Median time (95% CI)(months) | P-value log-rank | Median time (95% CI)(months) | P-value log-rank |
| All patients | 23 (21.161, 24.839) | 14 (12.659, 15.341) | 31 (26.797, 35.203) | |||
| No anti-inflammatory medication | 23 (20.780, 25.220) | 13 (11.564, 14.436) | 34 (28.401, 39.599) | |||
| Medication groups | ||||||
| Any glucocorticoid | 19 (14.030, 23.970) | 0.0252 | 16 (8.588, 23.412) | 0.8961 | 20 (13.708, 26.292) | 0.0018 |
| Any NSAID | 21 (16.922, 25.078) | 0.0449 | 13 (8.646, 17.354) | 0.1554 | 26 (18.86, 33.14) | 0.0149 |
| Low-dose aspirin | 21 (16.048, 25.952) | 0.0610 | 10 (6.946, 13.054) | 0.0285 | 25 (15.084, 34.916) | 0.0781 |
| Other nonselective NSAIDs | 19 (11.379, 26.621) | 0.0606 | 13 (6.991, 19.009) | 0.3157 | 26 (14.818, 37.182) | 0.0337 |
| Selective COX-2 inhibitors | 22 (14.415, 29.585) | 0.5529 | 10 (2.857, 17.143) | 0.6695 | 26 (15.873, 36.127) | 0.3469 |
P values bolded if <0.05.